Cohance Lifesciences Board Meeting on Nov 6 to Approve Unaudited Financials

Cohance Lifesciences Ltd has announced that its Board of Directors will convene on November 6, 2026. The primary agenda item is the consideration and approval of the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half-year ended September 30, 2026. The company also confirmed that the trading window, closed since September 28, 2026, for designated persons and their relatives, will remain shut until November 9, 2026.